How I approach B-lymphoblastic lymphoma in children.

Autor: Devine KJ; Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA., Fries C; Department of Pediatrics, Division of Hematology/Oncology, University of Rochester, Rochester, New York, USA., Hermiston M; Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of California San Francisco, San Francisco, California, USA., Wistinghausen B; Division of Oncology, Center for Cancer and Blood Disorders, Children's National Hospital, Washington, District of Columbia, USA.
Jazyk: angličtina
Zdroj: Pediatric blood & cancer [Pediatr Blood Cancer] 2023 Aug; Vol. 70 (8), pp. e30401. Date of Electronic Publication: 2023 May 09.
DOI: 10.1002/pbc.30401
Abstrakt: There are limited data pertaining to the prognostic features and optimal therapeutic approach for the 20%-25% of children with lymphoblastic lymphoma (LLy) who have the B-lymphoblastic subtype. Outcomes are favorable following treatment modeled after acute lymphoblastic leukemia (ALL) regimens, but prognosis is dismal after relapse, and there are no established features for predicting therapy response. Ongoing US and international trials will include the largest cohort of uniformly treated patients with B-LLy to date, providing an opportunity to define clinical and molecular predictors of relapse and to establish a standard of care for treatment to improve outcomes for this rare pediatric cancer.
(© 2023 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: